Par Drugs and Chemicals Limited

NSEI:PAR Rapporto sulle azioni

Cap. di mercato: ₹2.9b

Par Drugs and Chemicals Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Par Drugs and Chemicals ha un patrimonio netto totale di ₹856.3M e un debito totale di ₹0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente ₹1.0B e ₹159.8M. L'EBIT di Par Drugs and Chemicals è ₹194.1M rendendo il suo rapporto di copertura degli interessi 174.3. Ha liquidità e investimenti a breve termine pari a ₹366.5M.

Informazioni chiave

0%

Rapporto debito/patrimonio netto

₹0

Debito

Indice di copertura degli interessi174.3x
Contanti₹366.54m
Patrimonio netto₹856.32m
Totale passività₹159.79m
Totale attività₹1.02b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Apr 16
Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Apr 05
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Nov 03
Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

May 19
If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Mar 17
Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Oct 22
Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Aug 11
Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Jul 14
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Mar 31
Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Mar 05
Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Feb 06
Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Jan 10
Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Dec 13
How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ₹596.2M ) di PAR superano le sue passività a breve termine ( ₹124.4M ).

Passività a lungo termine: Le attività a breve termine di PAR ( ₹596.2M ) superano le sue passività a lungo termine ( ₹35.4M ).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: PAR è esente da debiti.

Riduzione del debito: PAR non ha debiti rispetto a 5 anni fa, quando il suo rapporto debito/patrimonio netto era 15.6%.

Copertura del debito: PAR non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.

Copertura degli interessi: PAR non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.


Bilancio


Scoprire le aziende sane